[go: up one dir, main page]

WO2003102165A3 - IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE - Google Patents

IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE Download PDF

Info

Publication number
WO2003102165A3
WO2003102165A3 PCT/US2003/005196 US0305196W WO03102165A3 WO 2003102165 A3 WO2003102165 A3 WO 2003102165A3 US 0305196 W US0305196 W US 0305196W WO 03102165 A3 WO03102165 A3 WO 03102165A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic
terminus
terminal cysteine
protein
particles stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/005196
Other languages
French (fr)
Other versions
WO2003102165A2 (en
Inventor
Ashley J Birkett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apovia Inc
Original Assignee
Apovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/080,299 external-priority patent/US20030175863A1/en
Priority claimed from US10/082,014 external-priority patent/US20030185858A1/en
Priority claimed from US10/274,616 external-priority patent/US20030202982A1/en
Application filed by Apovia Inc filed Critical Apovia Inc
Priority to AU2003213168A priority Critical patent/AU2003213168A1/en
Priority to EP03709214A priority patent/EP1517702A4/en
Publication of WO2003102165A2 publication Critical patent/WO2003102165A2/en
Priority to US10/787,734 priority patent/US7361352B2/en
Anticipated expiration legal-status Critical
Publication of WO2003102165A3 publication Critical patent/WO2003102165A3/en
Priority to US11/509,382 priority patent/US8017127B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid protein (HBc) is disclosed that is engineered for both enhanced stability of self-assembled particles and the display of an immunogenic B cell or T cell epitope, or both, such as a B cell epitope polypeptide of the influenza M2 protein and a T cell epitope of the influenza NP protein. An immunogenic epitope is peptide-bonded to one or more of the N-terminus, in the immunogenic loop or at the C-terminus of HBc, whereas the enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near the amino-terminus of the chimer molecule. Methods of making and using the chimers are also disclosed.
PCT/US2003/005196 2001-08-15 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE Ceased WO2003102165A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003213168A AU2003213168A1 (en) 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
EP03709214A EP1517702A4 (en) 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US10/787,734 US7361352B2 (en) 2001-08-15 2004-02-26 Influenza immunogen and vaccine
US11/509,382 US8017127B2 (en) 2001-08-15 2006-08-24 Influenza immunogen and vaccine

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/080,299 US20030175863A1 (en) 2001-08-15 2002-02-21 Influenza immunogen and vaccine
US10/082,014 US20030185858A1 (en) 2001-08-15 2002-02-21 Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US10/082,014 2002-02-21
US10/080,299 2002-02-21
US10/274,616 2002-10-21
US10/274,616 US20030202982A1 (en) 2001-08-15 2002-10-21 Influenza immunogen and vaccine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/274,616 Continuation-In-Part US20030202982A1 (en) 2001-08-15 2002-10-21 Influenza immunogen and vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/732,862 Continuation-In-Part US20040146524A1 (en) 2001-08-15 2003-12-10 Stabilized immunogenic HBc chimer particles

Publications (2)

Publication Number Publication Date
WO2003102165A2 WO2003102165A2 (en) 2003-12-11
WO2003102165A3 true WO2003102165A3 (en) 2005-01-06

Family

ID=29715970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005196 Ceased WO2003102165A2 (en) 2001-08-15 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Country Status (3)

Country Link
EP (1) EP1517702A4 (en)
AU (1) AU2003213168A1 (en)
WO (1) WO2003102165A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
EP3011969A1 (en) 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2008036146A2 (en) 2006-07-14 2008-03-27 Sanofi Pasteur Biologics Co. Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
KR20090096414A (en) 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 Recombinant rhino virus vectors
EP3115060A1 (en) 2008-04-18 2017-01-11 VaxInnate Corporation Deletion mutants of flagellin and methods of use
KR101634058B1 (en) 2008-12-09 2016-06-27 화이자 백신스 엘엘씨 IgE CH3 PEPTIDE VACCINE
CN102596236B (en) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 Antigenic Tau peptides and uses thereof
MX2012002639A (en) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Pcsk9 vaccine.
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
CN106279379B (en) * 2016-09-13 2020-05-22 华兰生物工程股份有限公司 Immunogen HM4-M2e, and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054689B1 (en) * 1998-02-12 2003-09-10 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US5990085A (en) * 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NEIRYNCK S. ET AL: "A universal influenza A vaccine based on the extracellular domain of the M2 protein", NATURE MEDICINE, vol. 5, no. 10, October 1999 (1999-10-01), pages 1157 - 1163, XP002196652 *
PUMPENS P. ET AL: "Hepatitis B virus core particles as epitope carriers", INTERVIROLOGY, vol. 38, 1995, pages 63 - 74, XP002903139 *
See also references of EP1517702A4 *
ZLOTNICK A. ET AL: "Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: Implications for morphogenesis and organization of encapsidated RNA", PNAS, vol. 94, September 1997 (1997-09-01), pages 9556 - 9561, XP002982400 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Also Published As

Publication number Publication date
WO2003102165A2 (en) 2003-12-11
AU2003213168A8 (en) 2003-12-19
AU2003213168A1 (en) 2003-12-19
EP1517702A4 (en) 2006-05-03
EP1517702A2 (en) 2005-03-30

Similar Documents

Publication Publication Date Title
WO2002014478A3 (en) IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY
WO2005055957A3 (en) Influenza immunogen and vaccine
WO2004075836A3 (en) STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2003102165A3 (en) IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
WO2004053091A3 (en) STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
AP2003002751A0 (en) Malaria immunogen and vaccine
WO2007011904A3 (en) Recombinant flu vaccines
MY149128A (en) A method for the mass production of immunoglobulin fc region deleted initial methionine residues
ATE475675T1 (en) USE OF PROCARIOTIC PLAGUE-LIKE PEPTIDES TO ENHANCE THE IMMUNOGENICITY OF ANTIGENS
WO2008138649A3 (en) Signaling peptides
WO2009130588A3 (en) Codon-optimzed hepatitis b virus core antigen (hbcag)
WO2006133911A3 (en) Hepatitis c virus nucleic acid vaccine
CY1109257T1 (en) CHEMICAL PROTEINS L1 OF JUV 16 HUMAN PATIENTS CONTAINING L2 Peptide, Similar to Virus Particles Prepared by
WO2003072731A3 (en) STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
CA2390082A1 (en) Novel hcv non-structural polypeptide
PH12021550898A1 (en) Virus-like particles of cmv modified by fusion
MY157396A (en) Novel fusion proteins and use thereof for preparing hepatitis c vaccines
WO2004005473A3 (en) Hcv fusion proteins with modified ns3 domains
MY197457A (en) Chimeric papillomavirus l1 protein
PE20020857A1 (en) FUSION PROTEINS WHOSE PART OF THE N-TERMINAL IS A DERIVATIVE OF HIRUDIN FOR THE PRODUCTION OF RECOMBINANT PROTEINS THROUGH SECRESSION BY YEAST
WO2009048633A3 (en) Chimeric chikungunya virus and uses thereof
PH12018502430A1 (en) Vaccines
GB2498323A (en) Generation of antigenic virus-like particles through protein-protein linkages
WO2008024518A3 (en) Hcv fusion polypeptides
WO2003072722A3 (en) IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003709214

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003709214

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP